PA
ABUS icon

Parallel Advisors’s Arbutus Biopharma ABUS Stock Holding History

Parallel Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.68K Sell
1,039
-165
-14% -$721 ﹤0.01% 3054
2025
Q4 		$5.79K Hold
1,204
– – ﹤0.01% 2794
2025
Q3 		$5.47K Sell
1,204
-116
-9% -$426 ﹤0.01% 2744
2025
Q2 		$4.08K Buy
1,320
+489
+59% +$1.62K ﹤0.01% 2809
2025
Q1 		$2.9K Hold
831
– – ﹤0.01% 2866
2024
Q4 		$2.72K Hold
831
– – ﹤0.01% 2862
2024
Q3 		$3.2K Hold
831
– – ﹤0.01% 2761
2024
Q2 		$2.57K Buy
831
+281
+51% +$843 ﹤0.01% 2734
2024
Q1 		$1.42K Hold
550
– – ﹤0.01% 2873
2023
Q4 		$1.38K Hold
550
– – ﹤0.01% 2876
2023
Q3 		$1.12K Hold
550
– – ﹤0.01% 2957
2023
Q2 		$1.26K Sell
550
-122
-18% -$318 ﹤0.01% 2873
2023
Q1 		$2.04K Buy
672
+122
+22% +$344 ﹤0.01% 2770
2022
Q4 		$1.28K Hold
550
– – ﹤0.01% 2837
2022
Q3 		$1K Sell
550
-169
-24% -$398 ﹤0.01% 2827
2022
Q2 		$2K Buy
719
+169
+31% +$433 ﹤0.01% 2521
2022
Q1 		$2K Hold
550
– – ﹤0.01% 2535
2021
Q4 		$2K Hold
550
– – ﹤0.01% 2644
2021
Q3 		$2K Hold
550
– – ﹤0.01% 2630
2021
Q2 		$2K Hold
550
– – ﹤0.01% 2516
2021
Q1 		$2K Hold
550
– – ﹤0.01% 2433
2020
Q4 		$2K Hold
550
– – ﹤0.01% 2254
2020
Q3 		$2K Buy
+550
New +$1.67K ﹤0.01% 2253

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Parallel Advisors's ABUS Position: Q1 2026 in Review

Parallel Advisors reduced its Arbutus Biopharma (ABUS) stake by 14% in Q1 2026, selling an estimated $721 and leaving 1,039 shares worth $4.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3054.

Parallel Advisors first reported a position in ABUS in Q3 2020 and has held it in 23 quarters since. The position peaked at $5.79K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Parallel Advisors held 1,039 shares of Arbutus Biopharma worth $4.68K as of Q1 2026.
  • Parallel Advisors sold 165 Arbutus Biopharma shares in Q1 2026, an estimated $721.
  • Arbutus Biopharma made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3054 holding.
  • Parallel Advisors first reported a position in Arbutus Biopharma in Q3 2020 and has held it in 23 quarters since.
  • Parallel Advisors's Arbutus Biopharma position peaked at $5.79K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.